TerminatedInterventionalPhase 2Updated Jan 20, 2012
Safety and Efficacy of AGN 203818 in Patients With Painful Diabetic Peripheral Neuropathy | NCT00381719 | Trialant
CompletedInterventionalPhase 2Updated Jan 7, 2008
Safety and Efficacy of AGN 203818 in Patients With Painful Diabetic Peripheral Neuropathy
ClinicalTrials.gov ID
NCT00381719
Lead Sponsor
AllerganINDUSTRY
Overall Status
Completed
Study Type
Interventional
Phase
Phase 2
Enrollment
330Actual
Last Update Posted
Jan 7, 2008Estimated
Start Date
Oct 2006
Primary Completion Date
Nov 2007Actual
Completion Date
Nov 2007Actual
Brief Summary
This study will explore the safety and effectiveness of different doses of AGN 203818 in treating pain in patients with painful diabetic peripheral neuropathy